SonALAsense

About:

SonALAsense develops SDT (Sonodynamic Therapy) intended to turn glioblastoma multiforme (GBM) patients into cancer survivors.

Website: https://sonalasense.com

Twitter/X: sonalasense

Top Investors: K4 Forum Mumbai Network

Description:

SonALAsense develops SDT (Sonodynamic Therapy) intended to turn glioblastoma multiforme (GBM) patients into cancer survivors. It utilizes MRI-guided focused ultrasound (the device) in combination with aminolevulinic acid (a drug) to selectively target and kill tumor cells. Their use of an MRI-guided focused ultrasound device with ALA is a true drug-device combination, where both the drug and the device are required for a therapeutic effect. SDT has a well-elucidated mechanism of action (creation of reactive oxygen species). The company was founded in 2019 and is based in Berkeley, California.

Total Funding Amount:

$21.1M

Headquarters Location:

Berkeley, California, United States

Founded Date:

2019-01-01

Founders:

Stuart Marcus

Number of Employees:

1-10

Last Funding Date:

2022-01-06

IPO Status:

Private

Industries:

© 2025 bioDAO.ai